A 36-year-old male with Crohn's disease on chronic treatment with mesalazine and low dosages of prednisone was admitted due to repeated syncopes. Physical examination was normal and ECG showed trifascicular block (prolonged PR, anterior haemiblock, and complete right bundle branch block). Echocardiogram showed predominately anterior and septal hypertrophy, on a medio-basal level (Panel 1, Figures A and B) . Magnetic resonance imaging confirmed these findings, also revealing interatrial septal hypertrophy with a nodular formation in the lowest section (Panel 2, Figure A ) and myocardial oedema (Panel 2, Figure B) . After gadolinium diethylenetriamine penta-acetic acid infusion, there was a perfusion defect in the hypertrophic areas (Panel 2, Figure C ) and epicardial late gadolinium enhancement in the anterior wall, and practically transmural extension in the interventricular and interatrial septum (Panel 2, Figures D-F) . As myocarditis was suspected as an adverse reaction associated to treatment with mesalazine, the drug was withdrawn. Owing to persistent trifascicular block, a pacemaker was implanted. One year later, the ECG had no conduction disorders and the echocardiogram showed thinning with dyskinesia of the previously hypertrophic areas (Panel 1, Figures C and D) .
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Myocarditis associated with mesalazine is a rare phenomenon, although it is potentially serious. It has previously been described as a mechanism of hypersensitivity to the drug, which would make the association independent of the dose received, and which could be triggered at the start of treatment or subsequently. This is the first time in the literature that a case has been described with MRI of myocarditis due to mesalazine. MRI studies allow precise diagnoses to be given and can serve as a guide to evaluate treatment efficacy and to manage myocardial biopsies.
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